Kaitlyn D’Onofrio

DocwireNews

An analysis of new data concluded that <a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/aspirin-increase-internal-bleeding-risk/">aspirin</a> may not be an effective prevention strategy for cardiovascular disease and cancer.The study authors pointed out that recent research does not appear to support the claim derived from older data that aspirin is effective in prevention. Therefore, they sought to &ldquo;compare benefits and harms of aspirin for primary prevention before and after widespread use of statins and colorectal cancer screening.&rdquo;According to a <a href="https://www.eurekalert.org/pub_releases/2019-12/oupu-amn120919.php">press release</a> on the findings, &ldquo;Nearly half of adults 70 years and older have reported taking aspirin daily even if they don&rsquo;t have a history of heart disease or stroke. Overall, an estimated 40% of adults in the United States take aspirin for primary prevention of cardiovascular diseases, making it one of our most commonly used medications.&rdquo;For the current analysis, the researchers compared two sets of data from studies evaluating aspirin for primary prevention: data from studies that recruited patients from 2005 onward, and previous individual patient data (IPD) meta-analyses that recruited patients between 1978 and 2012. They synthesized the current data using random-effects models. Outcomes included vascular (major adverse cardiovascular events [MACE], myocardial infarction [MI], and stroke), bleeding, cancer, and mortality outcomes.IPD analyses of older aspirin studies encompassed 95,456 total patients evaluated for cardiovascular prevention and 25,270 for cancer mortality. There were four contemporary aspirin studies encompassing 61,604 total patients. The relative risks (RRs) for vascular outcomes for older versus newer studies were: MACE, 0.89 (95% confidence interval [CI], 0.83-0.95) vs. 0.93 (95% CI, 0.86-0.99); fatal hemorrhagic stroke, 1.73 (95% CI, 1.11-2.72) vs. 1.06 (95% CI, 0.66-1.70); any ischemic stroke, 0.86 (95% CI, 0.74-1.00) vs. 0.86 (95% CI, 0.75-0.98); any MI, 0.84 (95% CI, 0.77-0.92) vs. 0.88 (95% CI, 0.77-1.00); and non-fatal MI, 0.79 (95% CI, 0.71-0.88) vs. 0.94 (95% CI, 0.83-1.08). Newer studies did not observe a large decrease in cancer mortality (RR=1.11; 95% CI, 0.92-1.34). A significant increase was observed in major hemorrhage (older studies RR=1.48; 95% CI, 1.25-1.76 vs. newer studies RR=1.37; 95% CI, 1.24-1.53). No impact was observed on all-cause mortality, cardiovascular mortality, fatal stroke, or fatal MI.The results of the study were published in <a href="https://academic.oup.com/fampra/advance-article-abstract/doi/10.1093/fampra/cmz080/5637484?redirectedFrom=fulltext">Family Practice</a>.The study authors stated in summary, &ldquo;Per 1200 persons taking <a href="https://www.docwirenews.com/cardiology/new-prevention-guidelines-emphasize-lifestyle-changes-discourage-daily-aspirin/">aspirin</a> for primary prevention for 5 years, there will be 4 fewer MACEs, 3 fewer ischaemic strokes, 3 more intracranial haemorrhages and 8 more major bleeding events. Aspirin should no longer be recommended for primary prevention.&rdquo;

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Aspirin No Longer Recommended for Primary Cardiovascular Prevention

Cardiology

An analysis of new data concluded that aspirin may not be an effective prevention strategy for cardiovascular disease and cancer. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe